In 2022, the global market for single-use bioreactors is estimated to be worth USD 3,432.4 million and will grow at a compound annual growth rate of 18.8% between 2022 and 2030 while reaching USD 13,595.9 million by 2030.

This growth of the market can be credited to the increasing demand for biosimilar and biologic medications because of the growing occurrence of communicable and chronic illnesses, and the obtainability of pioneering single-use bioreactors.

A substantial increase in the acceptance of these bioreactors by small & medium-sized enterprises and startups has been witnessed. This is mainly due to the establishment of a biomanufacturing facility needing significant capital funds.

Furthermore, small-scale biopharmaceutical, biotechnological, and pharmaceutical organizations make fewer batches yearly. Also, for these small-scale companies, creating a stainless-steel facility can be expensive. Therefore, developing businesses are accepting single-use systems in their industrial units, as they need fewer investments, as cleaning, validation sterilization and changeover are not required in these facilities.

Download free sample copy of this report: https://www.psmarketresearch.com/market-analysis/single-use-bioreactors-market/report-sample

In 2022, based on product type, the system category dominates the industry, generating a revenue share of more than 55%. This can be credited to the wide usage of these systems in biopharmaceutical industrial facilities needing a high quantity of products. Moreover, these systems are versatile, economical, and have large manufacturing abilities.

Furthermore, there is a rising requirement for fast growth of biotherapeutics, like enzymes, antibodies, enzymes, and hormones, in huge sizes, which can be formed in such bioreactors. Thus, all these reasons are driving the development of the industry in this category.

In 2022, based on the type segment, stirred-tank bioreactors generated the largest revenue share, at 45%. This is credited to many benefits provided by them like low working prices, good liquid mixing capability and oxygen transfer, and simple scale-up.

The category of mammalian cells dominated the market in 2022 on the basis of the cell type segment. That's because these cells are being used extensively in the development of recipient proteins and biological therapies. In the study, it was observed that mammalian cell culture is used to produce a high number of biotherapeutic candidates.

The highest market share in the world belongs to North America. The increased prevalence of diabetes, the presence of key players and high-quality healthcare services, technological progress in this field as well and a strong R&D initiative such as availability and funding for research will be attributed to these factors.

The United States plays a crucial role in expanding the North American market. This is due to an increasing adoption of modern technology, a higher awareness of ailment prevention amongst the overall population, an excessive degree of government support, and advanced healthcare centers within the use.